Rocklatan header logo
MENU CLOSE

Reduce treatment burden with once-daily Rocklatan®1

Rocklatan® is a once-daily ophthalmic solution that contains 0.02% netarsudil ophthalmic solution and 0.005% latanoprost ophthalmic solution.2 What does that mean for patients?

QD dosing icon

Once-daily dosing from a single bottle means Rocklatan® may help patients1:

  • Reduce treatment burden with a once-a-day dosing schedule
  • Improve adherence with the convenience of a single bottle
  • Reduce the risk of disease progression through improved adherence

Help improve overall treatment compliance for patients with open-angle glaucoma and ocular hypertension1


Administration and Storage2

Rocklatan® only requires one drop of medication per day and should be taken in the evening.

If one dose is missed, treatment should continue with the next dose in the evening.

If Rocklatan® is to be used concomitantly with other topical ophthalmic products, administer each product at least 5 minutes apart.

The dosage for Rocklatan® should not exceed once daily.

Storing Rocklatan®

Protect from light. Store Rocklatan® in the refrigerator (36°–46°F).

For any additional questions on storage or handling, view full Prescribing Information.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

  • Pigmentation changes
  • Eyelash changes
  • Intraocular inflammation
  • Macular edema
  • Herpetic keratitis
  • Bacterial keratitis
  • Contact lens wear

Adverse reactions

Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.

Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.


IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

  • Pigmentation changes
  • Eyelash changes
  • Intraocular inflammation
  • Macular edema
  • Herpetic keratitis
  • Bacterial keratitis
  • Contact lens wear

Adverse reactions

Rocklatan®: The most common ocular adverse reaction is conjunctival hyperemia (59%). Five percent of patients discontinued therapy due to conjunctival hyperemia. Other common ocular adverse reactions were: instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

Netarsudil 0.02%: Instillation site erythema, corneal staining, increased lacrimation and erythema of eyelid.

Latanoprost 0.005%: Foreign body sensation, punctate keratitis, burning and stinging, itching, increased pigmentation of the iris, excessive tearing, eyelid discomfort, dry eye, eye pain, eyelid margin crusting, erythema of the eyelid, upper respiratory tract infection/nasopharyngitis/influenza, photophobia, eyelid edema, myalgia/arthralgia/back pain, and rash/allergic reaction.

Please click here for full prescribing information for Rocklatan®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of Rocklatan® should not exceed once daily. Rocklatan® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

References:

  1. Prum B Jr, Rosenberg L, Gedde S, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines. Ophthalmology. 2016;123(1):P41-P111.
  2. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.